<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="357">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126399</url>
  </required_header>
  <id_info>
    <org_study_id>COL-101-ROSE-301+302</org_study_id>
    <nct_id>NCT00126399</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>CollaGenex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CollaGenex Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of 40 mg doxycycline
      controlled-release capsules administered once daily for the treatment of rosacea compared
      with a placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date>April 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in total inflammatory lesion count</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in erythema scale scores</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in the investigator's global assessment (IGA) score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients being clear or near-clear at endpoint</measure>
  </secondary_outcome>
  <enrollment>528</enrollment>
  <condition>Rosacea</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Healthy patients with rosacea

          -  Males and females ≥18 years of age

          -  10 to 40 papules and pustules and ≤2 nodules

          -  Score of 2 to 4 on the IGA

          -  Presence of telangiectasia

          -  Moderate to severe erythema

        Main Exclusion Criteria:

          -  Use of topical acne treatments or topical or systemic antibiotics

          -  Use of systemic retinoids within 90 days of baseline

          -  Use of an investigational drug within 90 days of baseline

          -  Pregnant or nursing women

          -  Women of childbearing potential not using an adequate form of contraception

          -  Change in method of contraception within 4 months of baseline

          -  Known hypersensitivity to tetracyclines

          -  Surgeries that bypass or exclude the duodenum or achlorhydria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2005</verification_date>
  <lastchanged_date>August 18, 2005</lastchanged_date>
  <firstreceived_date>August 2, 2005</firstreceived_date>
  <keyword>rosacea</keyword>
  <keyword>acne rosacea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
